Pulmonx Corporation

LUNG

$2.26

-0.88%

N/A-$0.02

Healthcare

Medical - Devices

NASDAQ

Active Trading

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. ...

CEO Profile of LUNG

Glendon E. French

Pulmonx Corporation

Tenure 12yKey-man risk: Medium

Glen French is a known quantity for investors, offering stability and deep domain expertise at a critical junction for Pulmonx. The success of his current mandate depends on his ability...

Key Risk

•Revenue volatility in the medical device sector

•Long-term path to profitability remains challenging

Key Tailwind

•Well-established core product in Zephyr Valve

•Strong clinical evidence base backing the tech

•Experienced leadership at the helm

Glendon E. French

Pulmonx Corporation (LUNG) · NASDAQ

Tenure 12 yearsNon-founder CEOKey-man risk: Medium

B.A. in History, Dartmouth College

glen-french-565a0161

Origin Story

A veteran medical device executive who led Pulmonx through a long commercialization phase, guided it to a 2020 IPO, and returned to the helm in 2025 to stabilize operations.

First Break: Co-founder and CEO of Asthmatx, which was acquired by Boston Scientific.

Path to CEO: French has over 30 years in the medical device sector. After leading Asthmatx to a successful exit, he joined Pulmonx in 2014 as President and CEO, steering the company through critical clinical trials, international expansion, and the 2020 Nasdaq IPO. He retired in March 2024 but was reappointed in October 2025 following a leadership transition period.

Original Vision: Commercializing minimally invasive technologies for chronic obstructive pulmonary disease (COPD), specifically the Zephyr Valve.

Glen French is a long-standing fixture in interventional pulmonology. After a successful tenure at Asthmatx, he joined Pulmonx in 2014, tasked with bringing the Zephyr Valve system to the U.S. market. His career is marked by expertise in navigating complex clinical and regulatory pathways, culminating in the successful 2020 IPO. His return to the company in 2025 underscores his role as the architect of the firm's commercialization strategy.

medtech veteranturnaround executiveserial entrepreneur

Investment Take

Glen French is a known quantity for investors, offering stability and deep domain expertise at a critical junction for Pulmonx. The success of his current mandate depends on his ability...

Key Tailwinds

Well-established core product in Zephyr Valve

Strong clinical evidence base backing the tech

Experienced leadership at the helm

Key Risks

Revenue volatility in the medical device sector

Long-term path to profitability remains challenging

Reliance on a specific domain expert for executive continuity

Career History

A career focused exclusively on interventional pulmonology and medical device commercialization.

Pulmonx Corporation

Initiative: President & CEO

Period: 2014–2024, 2025–Present

Event: Led IPO, commercialized Zephyr Valve globally, reappointed to restore growth.

Asthmatx

Initiative: Co-founder & CEO

Period: Prior to 2014

Event: Led the company to acquisition by Boston Scientific.

medical devicesinterventional pulmonology

Company Performance

Performance is currently in a recovery phase, with leadership focused on stabilizing sales and managing EBITDA losses.

Revenue: Experienced 20%+ CAGR during his initial tenure, currently navigating post-2025 management transition with revenue estimates around $90M-$92M for 2026.

Profitability: Operating at a net loss; Q1 2026 adjusted EBITDA loss was $8.5M as the company balances growth investment with cost discipline.

Stock: Stock has been volatile since the 2020 IPO, reflecting the challenges of scaling a commercial-stage medtech company.

•2020 IPO execution

•International commercial expansion

•Maintained board presence throughout leadership changes

•Revenue growth deceleration in 2024-2025

•Persistent net losses

commercial-stagegrowth-focused

Management Ability

Regarded as a stabilizing force and an industry expert with deep domain-specific knowledge.

Style: Operator and domain expert.

French's management style is centered on operational continuity and deep technical expertise in his sector. He is known for building teams capable of navigating rigorous regulatory and clinical environments. His return to the CEO role suggests the board prioritizes his historical familiarity with the company's culture and product ecosystem over outside disruption.

domain expertoperational focus

Capital Allocation

Disciplined approach to R&D and clinical investment, balanced against the need to scale commercial operations.

Focuses capital on core Zephyr Valve commercialization while balancing high operating expenses.

Capital allocation under French has historically prioritized R&D and clinical evidence generation to secure payer coverage. As a commercial-stage company, Pulmonx remains loss-making, and French’s current mandate involves optimizing the cost structure to improve the path to profitability.

capital disciplinecommercialization

Fundraising & Financing

Successful track record of institutional fundraising and public market navigation.

IPO: Successfully listed on NASDAQ in 2020.

Dilution: Moderate, consistent with a growth-stage medical device company.

French has a strong track record of raising capital to support the long clinical development cycle of Pulmonx's technology. His ability to secure and maintain investor confidence is evidenced by his re-appointment to the CEO role during a period of corporate transition.

capital marketsinvestor trust

Governance & Control

Standard public company governance; no outsized dual-class voting control noted.

Pulmonx follows standard corporate governance practices. French holds a position on the Board, maintaining strong alignment with company strategy, which was reinforced by his re-appointment as CEO while remaining a board member.

governanceboard alignment

Health & Succession

No public health concerns; succession risk currently managed by his return.

Health Status: no public concerns

Key-man Risk: Medium

French is a highly experienced executive, but his repeated cycling into and out of the CEO role highlights a dependency on his specific leadership.

key-man risk

R&D & Tech Vision

Deep focus on clinical evidence to support the Zephyr Valve pipeline.

Sustained investment as % of revenue to maintain innovation advantage.

Zephyr Valve system: Succeeded; global commercial standard.

High; focuses on proven pathways and clinical efficacy.

French's innovation philosophy is less about high-risk R&D and more about rigorous clinical development to prove efficacy for existing technology. This approach has proven successful in gaining institutional and regulatory traction.

clinical innovationevidence-based

Talent Recruitment

Strong reputation for retaining domain experts and industry veterans.

High caliber; emphasizes experience in medical device commercialization.

Retention: Strong, evidenced by his ability to step back into the CEO role.

French places a premium on building teams with deep medical and commercial expertise. His ability to attract and retain talent is a key component of the company's organizational stability, and his return to leadership suggests strong alignment with the existing executive bench.

talent retentionexperienced team

Strengths

Deep domain expertise and intimate familiarity with the company's history and product.

Domain expertise: Over 30 years of specialized experience in interventional pulmonology.

Stability: Ability to restore continuity and confidence as a former CEO returning to the firm.

medtech expertindustry veteran

Weaknesses & Failures

Struggles with sustained, profitable scaling and revenue consistency.

Operational scaling

Difficulty in consistently scaling top-line growth and achieving net profitability.

Example: Deceleration of growth in 2024-2025.

growth decelerationprofitability

Marketing & Brand

Marketing is heavily reliant on clinical evidence and physician advocacy to build market adoption.

The brand is synonymous with the Zephyr Valve in the interventional pulmonology space.

Marketing strategy under French relies on building a robust clinical evidence base, which is crucial for influencing physician adoption and payer coverage. The company positions itself as a specialized technology provider for severe emphysema, focusing on targeted medical centers and KOLs (Key Opinion Leaders).

clinical evidenceniche marketing

PR & Communication

Experienced communicator with a calm, professional tone suitable for an investor-facing role.

Media Reputation: positive

French is a seasoned communicator who manages earnings calls and investor expectations with professional clarity. His reputation as a founder and industry veteran provides significant credibility with the investor community, even during challenging periods of management transition.

professionalcredible

Supply Chain of LUNG

Upstream / Downstream / Proxies

Upstream

Confluent Medical TechnologiesTE Connectivity / Creganna MedicalNYSE:TELSilicone component manufacturer (unnamed single-source supplier)Chartis Console electronics/component suppliers (multiple)Jaeger Medical (Trudell Medical Group)ATI Inc. (Allegheny Technologies)NYSE:ATISpecialty medical silicone raw material suppliers (e.g., Dow, Wacker)Unconfirmed

Downstream

U.S. Hospitals & Treatment Centers (direct customers)International distributors (Europe, Middle East, Africa)China distributor (unnamed)Japan distributor / direct subsidiary presenceAsia-Pacific distributors (via Pulmonx Hong Kong Limited)Jaeger Medical (Trudell Medical Group)

Proxies

Olympus CorporationTSE:7733Boston Scientific CorporationNYSE:BSX Inspira Technologies Oxy B.H.N. Ltd.NASDAQ:IINN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer